Please ensure Javascript is enabled for purposes of website accessibility

Paysign (PAYS) Q1 2021 Earnings Call Transcript

By Motley Fool Transcribing - May 11, 2021 at 11:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

PAYS earnings call for the period ending March 31, 2021.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Paysign (PAYS 5.88%)
Q1 2021 Earnings Call
May 11, 2021, 5:00 p.m. ET


  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Hello, and welcome to the Paysign's first-quarter 2021 conference call and webcast. At this time, all participants are in a listen-only mode. [Operator instructions] A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

This presentation may include forward-looking statements to the extent that the information presented in this presentation discusses financial projections, information, or expectations about the company's business plans, results of operations, the impact of COVID-19, returns on equity, expected gross margins, markets, or otherwise make statements about future events. Such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as should, may, intends, anticipates, believes, estimates, projects, forecasts, expects, plans, and proposals. Although the company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.

You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading risk factors and elsewhere in the Form 10-K. Forward-looking statements speak only as of the date of the document in which they are contained, and the company does not undertake any duty to update any forward-looking statements except as may be required by law. This presentation also includes adjusted EBITDA, a non-GAAP financial measure that is neither prepared in accordance with nor an alternative to financial measures prepared in accordance based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies. It's now my pleasure to turn the call over to CEO, Mark Newcomer.

Please go ahead, sir.

Mark Newcomer -- Co-Founder, Vice Chairman, and Chief Executive Officer

Thank you, Kevin. Good afternoon, everyone, and thank you for joining us for Paysign's first-quarter 2021 earnings call. I am Mark Newcomer, chief executive officer. And joining me this afternoon is Jeff Baker, our chief financial officer.

The first quarter is typically a seasonally weaker quarter for our business due to the timing of tax refunds and the impact they have on plasma donations. This weakness was intensified this quarter due to the added effects of the pandemic-related stimulus payments and unemployment benefit extensions. Our first-quarter plasma funds loaded was down 2.5% from the year-ago period and down 6.8% from the previous quarter. We believe that plasma donations will return to normal levels as these stimulus packages expire and consumers return to the plasma centers.

In the quarter, we onboarded three new plasma centers, bringing our total number of centers to 343. Additionally, we signed four new plasma clients. They are all new entrants in the plasma collection space, and each have aggressive growth plans with initial centers expected to go live in the second quarter. Our plasma pipeline remains strong, and we remain optimistic in the future of the segment's growth as we are seeing an increase in new center builds from our existing plasma clients.

We expect to add a total of 60 new plasma centers this year exiting 2021 with at least 400 centers. Our patient affordability offerings continue to grow. We are seeing very positive feedback from the market related to our product offerings and partnership strategy and that is reflected in our sales pipeline. During the first quarter, we developed and launched a new voucher program for an existing client.

This program addition reflects upon the ability of our sales, client services, and operational teams to build trust and confidence in our offerings, allowing us to capture additional revenue from existing clients. We officially launched two additional programs in the first quarter, a pharmacy claims-based program and a hybrid pharmacy and medical claims-based program. We believe that hybrid and medical claims-based programs represent an underserved portion of the patient affordability market. Our product development continues to focus on the unique products, services, and relationships we can build to accommodate the needs of this growing vertical.

Overall, we are pleased with the continued growth of the patient affordability vertical and are excited about the continued pipeline growth. We have the utmost confidence in our sales, client services, and operational teams to retain and grow our existing patient affordability portfolio of clients by continuing to provide industry-leading insights and an outstanding client and patient experience. We're beginning to see traction with our digital bank account product Paysign Premier. We signed three new clients this quarter and have additional deals in the pipeline.

We continue to execute on our product strategy to enhance the product features by adding account-to-account transfers. Additionally, we signed two new deals for our business expense product to be used for T&E, per diem, vendor payments, and small expense purchases. While it is still early days for these products and it will take some time for them to ramp up, we are excited about the interest in them and the opportunity it brings us to expand into other verticals. With that, I'll pass it over to Jeff to give you a breakdown of our numbers.

Jeff Baker -- Chief Financial Officer

Good afternoon. The revenue and operating performance in the first quarter were in line with our expectations given the seasonally weak period driven by tax rebates, coupled with the impact of government stimulus measures related to COVID-19. Of our total revenues of 6.3 million, plasma revenue accounted for 5.4 million, or 86%. Pharma revenue was 883,000 and other revenue was 13,000.

Our gross margin for the quarter was 45.1%, reflecting a decrease in pharma revenues. We continue to hold SG&A expenses flat as an absolute dollar amount despite severance-related expenses and legal fees relating to our class action defense that negatively impacted the quarter by $450,000. Including these expenses, our adjusted EBITDA for the first quarter came in at a loss of $397,000, or a loss of $0.01 per fully diluted share. Adjusted EBITDA, which we defined as operating income plus depreciation, amortization, and stock-based compensation, and is a non-GAAP metric used by management to gauge the operating performance of the business.

These results compared unfavorably to pre-COVID first-quarter 2020 results of total revenues of $10.6 million, gross margins of 54.1%, and adjusted EBITDA of $2.6 million, or $0.05 per fully diluted share. First-quarter gross dollar volume declined 15.2% versus the year-ago period but increased sequentially by 2.2%. First-quarter purchase volume declined 13.1% versus the year-ago period and was unchanged versus the previous quarter. We did experience a sequential decline in our revenue conversion rate as we experienced a decrease in the number of cardholder purchase transactions, which negatively impacted our cardholder fees for the quarter.

We believe this is a seasonal trend as we experienced the same behavior during the same period last year. Taking a closer look at the plasma business for the quarter, revenues of $5.4 million were down $2.2 million from the same period last year. The average revenue per plasma center was $5,260 versus $8,589 last year. We exited the quarter with 343 centers versus 285 at the end of Q1 last year.

Turning your attention to the pharma business, first-quarter 2021 revenues of $768,000 decreased $2.1 million compared to first-quarter 2020, primarily driven by the change in accounting estimate last year and the termination of one program in December. We continue to win new mandates in the pharma business and expect new programs to launch in the third and fourth quarters of this year, giving us good momentum into 2022. Cost of revenues for the period decreased $1.4 million compared to the same period in the prior year, primarily due to the decline in plasma transactions as many of the plasma transaction costs are variable in nature. Gross profit for the quarter decreased 2.9 million compared to the same period last year resulting from the reduction in plasma and pharma revenue and the associated cost of sales as mentioned.

We continue to make significant investments in our business to give us the support and technological capabilities needed to efficiently grow the business and launch new prepaid programs. Thus, depreciation and amortization increased 18.6% year over year to $596,000. Regarding the health of our company, we exited the quarter with $6.6 million in unrestricted cash and zero debt, which is $1.2 million below our December ending balance. Based on our forecast, we believe we remain well-capitalized and positioned to weather any further impacts from COVID-19.

Lastly, I wanted to direct your attention to the press release, where we have laid out our thoughts for 2021. For the full year, we expect total revenue to be in the range of 29 million to 32 million, reflecting growth of 20% to 32%, and adjusted EBITDA of 350,000 to 1.9 million. Gross profit margins are expected to be 45% or increase 640 basis points over 2020. Operating expenses are expected to increase modestly to 18 million to 18.5 million, or 2% to 4.9%.

This outlook presumes that the second-quarter results are slightly better than the first-quarter results and that we began to see a recovery in the business in the third quarter when unemployment subsidies are scheduled to end in early September. With a non-COVID-19 impacted fourth quarter, we estimate our plasma revenue could reach $27.5 million for the full-year 2021 and increase by an additional $10 million in 2022. With that, I would like to turn the call over to the moderator for Q&A.

Questions & Answers:


Thank you. [Operator instructions] Our first question today is coming from Jon Hickman from Ladenburg Thalmann. Your line is now live.

Jon Hickman -- Ladenburg Thalmann

Hey. Thanks for taking my call. Can you hear me?

Mark Newcomer -- Co-Founder, Vice Chairman, and Chief Executive Officer

We can.

Jeff Baker -- Chief Financial Officer

We can hear you, Jon.

Jon Hickman -- Ladenburg Thalmann

OK. I was wondering if -- are you noticing any difference in different areas of the country based on COVID? Like are some areas mainly the Southeast or something doing -- is the plasma business doing better than, say, in California, etc.? Can you comment on that?

Mark Newcomer -- Co-Founder, Vice Chairman, and Chief Executive Officer

This is Mark. I would say, Jon, that I can't -- I haven't really seen anything that stood out to me that would show me there's a big difference on a regional basis. It seems to be kind of impacted across the boards.

Jon Hickman -- Ladenburg Thalmann

OK. And then so, your main competitor, now they're owned by a different outfit, is there anything you're seeing competitive wise, its difference in six months ago?

Mark Newcomer -- Co-Founder, Vice Chairman, and Chief Executive Officer

We're seeing additional opportunities for us to get our foot in the doors at additional companies. And outside of that, there's not too much I can say about it. But, you know, we're also seeing new entrants in the space, you know, more so than we've seen in the past. And we're successfully, you know, engaging with those new entrants.

Jon Hickman -- Ladenburg Thalmann

OK. That's it for me. Thanks.


Thank you. [Operator instructions] Our next question is coming from Michael Diana from Maxim Group. Your line is now live.

Michael Diana -- Maxim Group -- Analyst

OK. Thank you. Jeff, I just want to be clear on your plasma revenue guidance for 2022. Are you saying '21 could be 27.5 million and then '22 could be $37.5 million?

Jeff Baker -- Chief Financial Officer

Yeah, Michael, that's exactly right. So if you look at what's happened, you know, you'll see first quarter this year, second quarter, and into most of the third quarter, we think it's going to be impacts from COVID. When we come into the fourth quarter, the fourth-quarter number you get should be a non-COVID-impacted quarter. So, you know, obviously, you'll build that into, say, listen at least one right -- normal quarter like we had prior to COVID.

Michael Diana -- Maxim Group -- Analyst

Sure. Yeah.

Jeff Baker -- Chief Financial Officer

And then you layer that in, so you'll have, you know, easier comps in the first quarter, second quarter, and third quarter of 2022. And then fourth quarter you get kind of your industry growth say for all the -- you know, any of the centers, additional centers we had during the period.

Michael Diana -- Maxim Group -- Analyst

All right. OK, great. And your expenses for severance and the lawsuit you had in this quarter, did the lawsuit expenses continue?

Jeff Baker -- Chief Financial Officer

So, you know, that depends. When we've disclosed the lawsuits in our filings that are out there and, you know, we'll have to just play, see how that plays out. You know, it's about all I can say about it because, you know, it's an ongoing issue but -- yeah.

Michael Diana -- Maxim Group -- Analyst

Sure. OK, great. Thank you.

Jeff Baker -- Chief Financial Officer

All right, Michael.


[Operator instructions] We reached the end of our question-and-answer session. I'd like to turn the floor back over to Mark for any further or closing comments.

Mark Newcomer -- Co-Founder, Vice Chairman, and Chief Executive Officer

Thank you very much, Kevin. I'd like to reiterate that we are very pleased with our growing sales pipeline and the strides we've made in our patient affordability offerings. I would like to thank the Paysign team for their dedication and all their hard work. Thank you for your continued interest, your questions, and your participation in this earnings call.

Stay safe. Have a nice evening, and we look forward to next quarter's call.


[Operator signoff]

Duration: 17 minutes

Call participants:

Mark Newcomer -- Co-Founder, Vice Chairman, and Chief Executive Officer

Jeff Baker -- Chief Financial Officer

Jon Hickman -- Ladenburg Thalmann

Michael Diana -- Maxim Group -- Analyst

More PAYS analysis

All earnings call transcripts

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PaySign, Inc. Stock Quote
PaySign, Inc.
$2.87 (5.88%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.